Cabio Biotech Wuhan Co Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.034x

Cabio Biotech Wuhan Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Cabio Biotech Wuhan Co Ltd (688089) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥56.10 Million ≈ $8.21 Million USD) by net assets (CN¥1.64 Billion ≈ $239.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Cabio Biotech Wuhan Co Ltd (2013–2024)

Cash flow conversion efficiency of Cabio Biotech Wuhan Co Ltd from 2013 to 2024. This chart illustrates how Cabio Biotech Wuhan Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 688089 share price today for real-time trading data and today's change.

Cabio Biotech Wuhan Co Ltd Cash Flow Conversion Ratio Explained

Cabio Biotech Wuhan Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Cabio Biotech Wuhan Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cabio Biotech Wuhan Co Ltd ranked by their cash flow conversion efficiency. Also see Cabio Biotech Wuhan Co Ltd stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
VietinBank Securities JSC VN:CTS	-4.276x
Taiyen Biotech Co Ltd TW:1737	0.015x
Olimpo Real Estate SA MC:YORE	0.026x
Studio City International Holdings Ltd NYSE:MSC	0.015x
GoldQuest Mining Corp. V:GQC	-0.067x
Red Hill Minerals Ltd AU:RHI	0.084x
Jikai Equipment Manufacturing Co Ltd SHE:002691	-0.008x
Avita Medical Inc AU:AVH	0.411x

Annual Cash Flow Conversion Efficiency for Cabio Biotech Wuhan Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Cabio Biotech Wuhan Co Ltd from 2013 to 2024. Review Cabio Biotech Wuhan Co Ltd (688089) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.57 Billion ≈ $229.67 Million	CN¥173.04 Million ≈ $25.32 Million	0.110x	+139.09%
2023-12-31	CN¥1.49 Billion ≈ $218.60 Million	CN¥68.89 Million ≈ $10.08 Million	0.046x	-62.75%
2022-12-31	CN¥1.43 Billion ≈ $208.53 Million	CN¥176.40 Million ≈ $25.81 Million	0.124x	+65.60%
2021-12-31	CN¥1.38 Billion ≈ $202.20 Million	CN¥103.29 Million ≈ $15.11 Million	0.075x	-32.18%
2020-12-31	CN¥1.32 Billion ≈ $193.67 Million	CN¥145.88 Million ≈ $21.35 Million	0.110x	+4.38%
2019-12-31	CN¥1.25 Billion ≈ $182.85 Million	CN¥131.95 Million ≈ $19.31 Million	0.106x	-47.66%
2018-12-31	CN¥526.20 Million ≈ $77.00 Million	CN¥106.16 Million ≈ $15.53 Million	0.202x	-6.93%
2017-12-31	CN¥464.39 Million ≈ $67.96 Million	CN¥100.66 Million ≈ $14.73 Million	0.217x	+39.56%
2016-12-31	CN¥402.60 Million ≈ $58.91 Million	CN¥62.53 Million ≈ $9.15 Million	0.155x	+23.62%
2015-12-31	CN¥354.83 Million ≈ $51.92 Million	CN¥44.58 Million ≈ $6.52 Million	0.126x	+26.32%
2014-12-31	CN¥465.90 Million ≈ $68.18 Million	CN¥46.34 Million ≈ $6.78 Million	0.099x	+7.89%
2013-12-31	CN¥428.24 Million ≈ $62.66 Million	CN¥39.48 Million ≈ $5.78 Million	0.092x	--

About Cabio Biotech Wuhan Co Ltd

SHG:688089 China Biotechnology

Market Cap

$188.66 Million

CN¥1.29 Billion CNY

Market Cap Rank

#16510 Global

#4629 in China

Share Price

CN¥7.66

Change (1 day)

-1.54%

52-Week Range

CN¥6.98 - CN¥25.81

All Time High

CN¥48.06